- Howard Weisman presented PaxMedica’s goals and plans to investors at the H.C. Wainwright 25th Annual Global Investment Conference on September 12, 2023
- The presentation defined the company’s intention to generate significant funding for its ASD program by first gaining approval for suramin sodium in the treatment of a rare and deadly infection using the same drug
- The global ASD treatment market was valued at $2.02 billion and is expected to reach $3.28 billion by 2030
Howard Weisman, CEO of PaxMedica (NASDAQ: PXMD), a clinical-stage biopharmaceutical company focusing on the development of novel anti-purinergic therapies (“APTs”) for the treatment of Autism Spectrum Disorder (“ASD”) and other serious conditions with intractable neurological symptoms, recently participated in the H.C. Wainwright 25th Annual Global Investment Conference on September 12, 2023. He presented the company’s presentation to investors, expressing the company’s overall goals and plans for its lead programs – PAX-101 and PAX-102. He also participated in one-on-one meetings with investors registered at the conference.
As expressed by Mr. Weisman in the company’s presentation, PaxMedica plans to develop a drug for autism using suramin sodium, which was created in the past to treat Human African Trypanosomiasis (“HAT”), a deadly form of sleeping sickness, but was discontinued. PaxMedica plans to use data from…
NOTE TO INVESTORS: The latest news and updates relating to PXMD are available in the company’s newsroom at https://ibn.fm/PXMD
About BioMedWire
BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed)and Life Sciences sectors. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.
BMW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from BioMedWire, “Biotech” to 844-397-5787 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer
BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is powered by IBN